Telomere attrition
Telomeres are the protective caps on the ends of your chromosomes, and they shorten a little every time a cell divides — which is why they get sold as a clock you can read and reset. The reality is more humbling: longer is not simply better, the consumer tests are too noisy to act on, and chronic inflammation is the leading suspect for what wears the caps down, so the best protection is the same everyday programme that protects everything else.
Telomere attrition is the second of the twelve hallmarks of aging and the one with the most public mythology attached. A telomere is a stretch of repetitive DNA — the same short sequence repeated thousands of times — sitting at each end of a chromosome, where it does no coding work but instead acts as a disposable buffer that keeps the meaningful genome from being nibbled away. Every time a cell copies itself, the machinery that duplicates DNA can't quite finish the very tip, so a small piece of telomere is lost — the so-called end-replication problem — typically about 50 to 200 DNA "letters" (base pairs) per division.[1] Over many divisions the caps wear down, and once they get critically short the cell stops dividing or self-destructs. In effect, telomeres are a mitotic clock that counts how many times a cell has divided.
How confident should you be
Descriptive — Strong. Intervention — Caution, and the safe direction is indirect.
This page draws on evidence of very different strengths, and it is worth keeping them apart. That telomeres shorten with division, that critically short caps trigger senescence, and that inherited telomere-maintenance defects cause premature tissue failure are Strong — the last of these is a human natural experiment. The popular "longer is better" reading is contradicted by the genetic evidence, which shows a trade-off, lowering degenerative disease risk while raising the risk of cancer and some other conditions, such as high blood pressure, with roughly no net effect on lifespan. That lifestyle acts on telomeres mainly through chronic inflammation is plausible but unproven (Weak): it rests on one snapshot analysis of a national survey, and genetic studies have not confirmed it. Everything aimed at lengthening telomeres on purpose — supplements, gene therapy — is Weak / preliminary, and carries a Caution: the same property that lets tissues keep renewing is the one cancers exploit.
What telomeres actually do
The point of a telomere is to let the cell tell the difference between a natural chromosome end and a broken one. A free DNA end normally signals catastrophe — a double-strand break — and the cell will scramble to repair it, sometimes fusing chromosomes together with disastrous results. To prevent that, the telomere is wrapped in a six-protein collar (called shelterin) that folds the very tip back into a protective loop, hiding the end so the cell's damage alarms ignore it.[2] This is the link back to the first hallmark: a worn-out telomere stops looking like a capped end and starts looking like the kind of DNA break covered under genomic instability, which trips the same damage response.
So telomere shortening isn't just a passive countdown — it converts, at the end, into an active damage signal. That signal is what forces an old cell to make a decision: stop, or die.
From short caps to "zombie cells"
Strong — the mechanism is settled cell biology.
In the 1960s the cell biologist Leonard Hayflick showed that normal human cells grown in a dish can only divide a finite number of times — the Hayflick limit — before they stop. We now know telomere erosion is the mechanism behind that limit. When the caps reach a critical shortness, the cell enters replicative senescence: a permanent retirement in which it can no longer divide.[3]
Senescence is protective in the short term — a cell that can't divide can't become a tumour — but senescent cells don't die and go away. They linger, and they secrete a steady cocktail of inflammatory signals and tissue-degrading enzymes known as the senescence-associated secretory phenotype (SASP), in effect poisoning their neighbourhood. Accumulated across tissues over decades, this output is one of the engines of the chronic, sterile, low-grade inflammation — inflammaging — that drives much age-related disease. This is the same senescence-and-SASP machinery that genomic instability feeds into, which is why the two primary hallmarks converge on the same downstream damage.
Telomerase: the immortality enzyme we can't simply switch on
Strong — and the cancer trade-off is the reason nothing here is a consumer intervention.
There is an enzyme that rebuilds telomeres: telomerase, which adds the repeat sequence back onto the chromosome tip. The catch is that it is switched off in almost all adult body cells. It stays active mainly in the cells that give rise to eggs and sperm, in stem cells, and in immune cells when they are activated.[4] Even so, stem cells are not spared: blood-forming stem cells taken from adult bone marrow have shorter telomeres than those from fetal liver or umbilical-cord blood, a sign that their capacity to keep dividing also runs down with age.[5]
The obvious idea — just turn telomerase back on everywhere — runs straight into the reason evolution switched it off. Roughly 80 to 85% of human cancers switch telomerase back on, because limitless division is exactly what a tumour needs; most of the rest use a backup route called alternative lengthening of telomeres (ALT), which rebuilds telomeres by copying telomere DNA from one chromosome end to another.[6] The shutdown of telomerase in adult tissue is, in part, a tumour-suppression system: it puts a hard cap on how many times a rogue cell can multiply before its own telomeres force it to stop. Reactivating telomerase to fight aging therefore means loosening one of the body's built-in brakes on cancer. This tension is the central problem of the entire field.
The telomere paradox: longer is not "better"
Strong for the trade-off; the causal inference here is the best on the page.
The popular framing — short telomeres bad, long telomeres good, so lengthen them — is wrong, and the evidence against it is unusually clean. Telomere length has a trade-off relationship with health: too short is linked to degenerative, age-related disease, but too long is linked to cancer.
The strongest evidence comes from Mendelian randomization — a method that compares people by the telomere length they inherited at conception (which is randomly assigned and fixed for life), sidestepping the confounding that wrecks ordinary diet-and-disease studies. Those analyses paint a split picture. Genetically longer telomeres lower the risk of several wear-and-tear diseases: about 15% less coronary heart disease, much less idiopathic pulmonary fibrosis (a scarring lung disease), and less chronic kidney disease. They may also lower Alzheimer's risk, but only very slightly (about 3%), and that signal is the weakest of the group.[7] The same inherited advantage raises the risk of many cancers, including glioma, probably because cells that can keep dividing have more chances to pick up the mutations that start a tumour, and it also raises the risk of high blood pressure, metabolic syndrome and multiple sclerosis.[8] A scan of more than 1,000 health outcomes in about 400,000 UK Biobank participants, rechecked in a separate Finnish population, found the same split: genetically longer telomeres lowered the risk of five conditions, among them lung and digestive diseases and heart attack, but raised the risk of 23 others, mainly cancers, genitourinary diseases and high blood pressure.[9]
There is now a human natural experiment for the long end, too. People who inherit a faulty copy of POT1, a gene that normally restrains telomere lengthening, carry unusually long telomeres, and in affected families they develop blood-cell clones and a wide range of tumours, including lymphoma and other blood cancers.[10] Melanoma, sarcoma and thyroid cancer also cluster in these families, and in UK Biobank carriers had about eight times the usual risk of lymphoid blood cancers (lymphomas, lymphocytic leukaemias and myeloma), an estimated 45% having developed one by age 80.[11] It is the mirror image of the short-telomere diseases described below.
The net effect on overall lifespan is, strikingly, close to a wash. A large Mendelian-randomization analysis of about half a million UK Biobank participants found no clear effect of inherited telomere length on lifespan in either sex, although it could only have detected an effect of about 0.8 years or more. Lifespan was measured through parents' age at death rather than observed directly, which is a real limitation for a claim doing this much work. In women, longer telomeres went with slightly worse survival to late middle age, about three months less, with a similar but non-significant trend in men. The authors say this may be chance, and offer early cancer only as a possible explanation they did not test.[12] Measured telomere length also shows only a small overall effect. In about 470,000 UK Biobank adults, people with shorter telomeres had only a slightly higher risk of death overall, about 8% higher for each standard-deviation step shorter (a standard deviation is the typical spread between people). The links were stronger for deaths from lung and digestive disease, there was none for cancer deaths, and cancer itself cut both ways: cancer overall, oesophageal cancer and leukaemias were more common with shorter telomeres, while brain cancer and melanoma were more common with longer ones.[13] Where longer telomeres do seem to help is healthspan, meaning the years lived before a first major chronic disease. A genetic analysis drawing on about 300,000 UK Biobank participants found that people who inherited longer telomeres went longer before their first diagnosis of cancer, heart attack, heart failure, stroke, dementia, diabetes or chronic lung disease, or before death. The authors present this as consistent with a possible effect rather than proof.[14] That study did not look at total lifespan, so the contrast between better healthspan and unchanged lifespan comes from setting two separate studies side by side, not from one analysis. The body's optimum is a balance: long enough to keep tissues regenerating, short enough to retire dangerous cells. "More telomere" is not a goal; it is a different risk profile.
Lifestyle and telomeres: inflammation is the leading suspect
Weak — one cross-sectional analysis of a national survey, not a trial, and genetic studies have not confirmed it. The direction is plausible, but nothing here randomised anyone.
The older picture had diet and exercise protecting telomeres directly, mainly by mopping up the oxidative stress that frays the DNA tips. A newer, systems-level analysis suggests something different: behaviour may barely touch the chromosome end directly, and instead work one step upstream, by raising or lowering chronic inflammation. It is an idea worth taking seriously, not yet a finding.
A network analysis of 7,096 adults in the long-running US national health survey (NHANES) modelled all the variables at once and found that C-reactive protein (CRP) — the standard blood marker of systemic inflammation — was inversely linked to telomere length — most strongly in younger and middle-aged adults — while smoking, physical activity, sex, race, and socioeconomic status had almost no direct connection to telomeres at all: they connected to CRP, and CRP connected to the telomeres. Only a handful of dietary measures kept a direct link of their own. The most consistent three, higher fibre and caffeine intake and higher blood gamma-tocopherol (a form of vitamin E), went with shorter telomeres rather than longer, and the one link in the other direction, higher sodium intake, appeared only in young adults. Because antioxidants played almost no protective role, the authors read their results as pointing to inflammation, rather than oxidative damage, as the main thing that wears telomeres down.[15] That idea is plausible but unproven, because a single snapshot in time cannot show what causes what. Genetic studies have not settled it either. One looked at 41 inflammatory signalling molecules, including interleukin-6, and found at most weak links to telomere length;[16] another found a few inflammatory genes linked to telomere length, with some links running from telomeres to inflammation rather than the other way.[17] And in a two-year trial in healthy adults, calorie restriction did not slow telomere loss compared with normal eating.[18] Chronic infection fits the same suspicion: people living with HIV tend to have shorter telomeres, plausibly because constant immune activation keeps white blood cells dividing, but the studies are mostly single snapshots of very low quality and none tested that mechanism.[19]
The practical advice does not change: not smoking, a healthy weight, good sleep and managing stress are worth doing for many reasons. Just don't expect them to show up as a telomere number. Poor sleep shows a small link with shorter telomeres: a 2025 review of 29 studies covering about 400,000 people pooled 19 of them and found roughly 24% higher odds of telomere shortening with poorer overall sleep quality, and about 28% higher odds with more time awake during the night. These are observational findings, and the review included no trials testing whether better sleep protects telomeres.[20] Stress reduction has not passed a long-term trial test either: in a randomised trial in adults aged 65 and over, 18 months of meditation training made no difference to telomere length (more under mindfulness and meditation).[21]
Diet and exercise: what the trials actually show
Moderate for a link between a Mediterranean pattern and longer telomeres, though almost all of it is observational; Weak for exercise, where the pooled trials point to a small benefit held with low confidence.
Diet works mostly as a pattern, and single pills mostly don't. The Mediterranean dietary pattern has the most evidence behind it, though almost all of it observational: higher adherence is associated with longer telomeres across large cohorts, including a population-based analysis within the Nurses' Health Study.[22] A pooled analysis of eight cross-sectional studies (about 13,700 people) found the same direction, but the effect was small, was not significant in men, and in women lost significance once other factors were fully accounted for.[23] The link seems to come from the whole pattern rather than any one food: in the Nurses' Health Study women, the overall Mediterranean-diet score tracked longer telomeres, but none of its individual components did on its own.[24] A small pilot within the PREDIMED-Plus trial (69 adults with metabolic syndrome) compared a calorie-restricted Mediterranean diet plus encouragement to be more active with an unrestricted Mediterranean diet. Telomeres measured longer after a year in both groups, and the extra calorie cutting and activity advice made no difference. Because both groups ate a Mediterranean diet and nobody ate a comparison diet, the trial cannot show that the diet caused the change.[25] The case for the Mediterranean pattern still rests mainly on observational studies. On the other side, sugar-sweetened drinks, refined carbohydrate, and processed meat track with higher inflammation and shorter telomeres.[26] Among single supplements, the one notable exception so far is vitamin D. In a telomere substudy of the large VITAL trial, about 1,000 US adults aged 50 and over were randomly assigned to 2,000 IU of vitamin D3 a day or placebo, and separately to 1 g of fish-oil omega-3 a day or placebo, for four years. Blood-cell telomeres shortened about 140 base pairs less on vitamin D than on placebo, a difference only just statistically significant, while fish oil made no difference.[27] This is slower loss, not lengthening. It comes from a single substudy using a cheap but imprecise DNA-amplification (PCR) test, and nobody has shown that it changes any health outcome; more in the VITAL trial.
The exercise effect is plausible and may depend on the type of exercise. In a six-month randomised trial in previously inactive adults, aerobic endurance training and high-intensity interval training (HIIT) each raised telomerase activity two- to three-fold and lengthened telomeres — but resistance training did neither, tracking the sedentary controls.[28] The proposed reason is that the cardiovascular modalities raise blood-vessel shear stress and improve mitochondrial and inflammatory tone, whereas strength work mainly builds muscle locally. The pooled evidence is weaker and messier than that single trial. A 2024 meta-analysis of nine trials in healthy adults found no clear overall effect on telomere length.[29] A 2025 analysis of 16 randomised trials (about 1,900 people) did find a modest benefit: telomeres held up better with exercise, apparently only in programmes lasting at least 16 weeks, and telomerase activity rose with aerobic training but not clearly with resistance training.[30] A 2025 umbrella review of 22 studies also found a small positive effect, but the reviews it drew on ranged from critically low to moderate quality.[31] The studies disagree a lot with one another and most used the noisy PCR test, so the direction is a small benefit held with low confidence. The takeaway is not "lift less" — resistance training remains essential for muscle, bone, and insulin sensitivity — but that if telomere maintenance is a goal, aerobic and interval work are what the molecular data point to, and strength training should be paired with them rather than relied on alone.
Can you measure your own telomeres?
Weak — the consumer tests are too imprecise to act on. Caution applies to the marketing rather than the biology: the field has disclosed commercial interests, and a noisy number sold as a verdict buys false reassurance.
Telomere length looks like an ideal biomarker — a single number for biological age — which is why direct-to-consumer telomere tests exist. They are, for an individual, close to useless, and it's worth understanding why.
Almost all low-cost commercial kits use a PCR-based assay — a DNA-amplification method — that reports only an average telomere signal relative to a reference gene, across millions of mixed cells. It is cheap and scalable but noisy. When ten laboratories measured the same blinded DNA samples, PCR results varied by about 20% from lab to lab, roughly twice as much as older gel-based methods, and the absolute numbers could not be compared directly between labs, although most labs still ranked the samples in a similar order, and once results were converted to a common scale PCR was no less accurate than the older methods.[32] Even within one lab, repeat runs of the same sample varied by about 16% on average.[33] The clinical-grade method, a cell-by-cell fluorescence technique called flow-FISH, is the only telomere test validated for diagnosing genuine telomere diseases.[34] In a small study of people being tested for a suspected telomere disease, the cheap PCR method correctly flagged only 40% of those whose telomeres were below the tenth percentile, against 80% for flow-FISH. Both methods caught every case of extremely short telomeres, so the PCR method's misses fall in the short-but-not-extreme zone, where a borderline result is hardest to interpret.[35] The consequences for a healthy adult: there's no agreed reference range, the year-to-year change in one person is swamped by assay noise, and "watching your telomeres improve" on a supplement is measuring mostly random variation. Spend the money instead on established markers of inflammatory and metabolic health — high-sensitivity CRP, fasting insulin, a lipid panel — which are reliable and actionable. Even measured carefully in research cohorts, blood telomere length predicts poorly. Tracked against later deaths in three US cohorts, DNA-methylation "clocks" did better than telomere length, and telomere length did not even point the same way in every cohort.[36] In a Scottish cohort of older adults followed for 16 years, every aging marker tested was linked to risk of death except telomere length.[37]
It's also worth knowing who promotes the idea. Some of the most prominent scientific advocacy for telomere testing comes from researchers with a direct commercial stake in it: María Blasco, among the field's leading telomere biologists, co-founded Life Length, a company that sells telomere-length measurement — an interest disclosed in the declarations of the 2023 hallmarks paper she co-authored, alongside a review of hers arguing for telomeres as a clinical target.[38] See the hallmarks hub for the wider list of commercial interests among the framework's authors. That doesn't make the science wrong, but it's a reason to discount marketing that frames a noisy number as an actionable readout of your aging.
The therapeutic frontier
Weak throughout: the lengthening approaches rest on mouse data or small, seller-funded human trials, and the cancer question is unresolved in humans for every item.
Efforts to lengthen telomeres directly remain firmly experimental, and the cancer trade-off shadows all of them. Tellingly, the telomerase drug that has gone furthest in trials does the opposite: imetelstat blocks the enzyme to hold back a blood cancer (lower-risk myelodysplastic syndrome). In its main company-funded trial, 40% of patients went at least 8 weeks without a transfusion, against 15% on placebo, at the cost of frequent, severe drops in blood counts.[39]
- Telomerase-activating supplements. The best-known is TA-65, a compound purified from the Astragalus plant. In a year-long placebo-controlled trial in 117 adults aged 53 to 87 who carried cytomegalovirus, a common chronic virus, the 23 people on the low dose gained about 530 base pairs of average telomere length while the placebo group lost about 290; the four-times-higher dose showed no significant change, and 20 participants did not finish. Every author was funded by, employed by or consulting for TA Sciences, the company that sells the supplement, and Life Length, the testing firm mentioned above, did the measurements.[40] A later randomised trial, also maker-funded, in 90 heart-attack survivors over 65 missed its main immune-aging goal and did not measure telomeres.[41] Separately, a small study in hairless mice exposed to ultraviolet light, paid for by the manufacturer, found no overall difference in when skin tumours appeared, how many mice got them or total tumour load, though the mice given it before, during and after exposure had more tumours of 2 mm or larger at two time points (one of them only borderline); with ten mice per group, that cannot rule out harm.[42] The data are limited and mostly industry-funded, and the long-term cancer question in humans is unresolved; this is not a recommendable intervention.
- Gene therapy. Delivering the telomerase gene into the brain with a viral carrier eased some signs of neurodegeneration in mice bred to lack telomerase and so carry short telomeres, even though fewer than 5% of brain cells took up the gene, and the treated mice showed no rise in cancer.[43] The result is specifically about neurodegeneration linked to short telomeres, not aging in general. This is a genuine proof of concept, but it is mouse data; human safety, especially the long-term cancer question, is entirely unestablished.
- Senolytics. Rather than rebuilding telomeres, this approach clears the senescent cells that short telomeres produce, lowering the SASP inflammatory burden. The most-studied combination (dasatinib plus quercetin), along with fisetin, shows striking preclinical results and is in early human trials, but is not a routine intervention. The site covers it under cellular senescence and geroprotectors.
Telomeropathies: when the system breaks early
Strong — this is the human natural experiment.
The clearest proof that telomere maintenance gates human health comes from rare genetic diseases in which it fails. In dyskeratosis congenita and related "telomere biology disorders," inherited mutations in telomere-maintenance genes cause the caps to shorten far too fast. The classic signs, though not everyone has them, are abnormal nails, lacy skin discolouration and white patches in the mouth, and patients face an increased risk of bone-marrow failure, scarring of the lungs (pulmonary fibrosis), blood cancers, and head-and-neck or anogenital cancers.[44] Bone-marrow failure develops in more than 80% of cases of dyskeratosis congenita.[45] These conditions are, in effect, accelerated aging localised to the tissues that divide most — a human experiment confirming that when telomeres go, the tissues that depend on constant renewal go first.
Testing does matter for one group: people with lung scarring (pulmonary fibrosis) that runs in the family, or with unexplained bone-marrow failure. In adults, faulty telomere maintenance is the most common single-gene cause of inherited lung fibrosis,[46] and faults in telomere genes turn up in roughly 3 in 10 families affected by it.[47] For these patients a specialist genetic diagnosis matters, because the condition can affect other organs that need monitoring or treatment.[48] This is where the clinical-grade flow-FISH test described above earns its place.
These diseases are also where a telomere drug has been tested in people. Danazol, a synthetic male hormone, improved blood counts in about four in five patients with telomere-driven marrow failure, and the trial's PCR measurements suggested telomeres even lengthened.[49] On longer follow-up, though, the benefit faded once the drug stopped, and in the few patients retested with the more accurate flow-FISH method, telomeres held steady rather than lengthening.[50] In telomere-related lung scarring it was poorly tolerated: fewer than half of patients completed a year of treatment, and side effects alone made more than a third stop.[51] It is a specialist treatment for a rare disease, not an anti-aging drug.
What this does and doesn't tell you
What it tells you: telomere attrition is a real mechanism of aging, the mechanism that links cell division to senescence and inflammaging, and — through the accelerated-aging telomere diseases — demonstrably consequential for human health. It also tells you that "longer is better" is false (the optimum is a cancer-versus-degeneration trade-off), that chronic inflammation is the leading suspect for what wears telomeres down, though that rests on one cross-sectional analysis and genetic studies have not confirmed it, and that the familiar healthy habits are worth keeping for other reasons, though their effect on telomeres themselves is unproven. Pooled exercise trials point to a small benefit held with low confidence, with aerobic and interval work carrying what signal there is, so this is a lean rather than a finding.
What it doesn't tell you: that you should measure your own telomere length (the consumer tests are too noisy to act on), that any supplement safely lengthens telomeres or extends human life, or that telomere length is a master dial worth chasing. The honest position is that telomeres are a beautifully clear illustration of aging biology and a poor target for individual self-optimisation — a gap between scientific elegance and practical leverage that recurs throughout this field.
Further reading
- López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023.[52]
- Iskandar M, et al. A review of telomere attrition in cancer and aging: current molecular insights and future therapeutic approaches. Cancers (Basel) 2025.[53]
- Huang X, et al. The relationship between telomere length and aging-related diseases. Clin Exp Med 2025.[54]
- Chen B, et al. Association between genetically determined telomere length and health-related outcomes: a systematic review and meta-analysis of Mendelian randomization studies. Aging Cell 2023.[55]
- Schooling CM, et al. Biological aging and lifespan in men and women using a Mendelian randomization study. Hum Genomics 2025.[56]
- Feng B, et al. Genetically proxied leukocyte telomere length and epigenetic age acceleration in relation to healthspan: a Mendelian randomization study. Ann Hum Genet 2026.[57]
- Tedaldi AM, et al. Diet, lifestyle and telomere length: using copula graphical models on NHANES data. Aging (Albany NY) 2025.[58]
- Bär C, Blasco MA. Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. F1000Res 2016 — note the disclosed commercial interest in telomere measurement.[59]
- Galiè S, et al. Impact of nutrition on telomere health: systematic review of observational cohort studies and randomised clinical trials. Adv Nutr 2020.[60]
- Crous-Bou M, et al. Mediterranean diet and telomere length in Nurses' Health Study: population based cohort study. BMJ 2014.[61]
- Fernández de la Puente M, et al. Modulation of telomere length by Mediterranean diet, caloric restriction, and exercise: results from the PREDIMED-Plus study. Antioxidants (Basel) 2021.[62]
- Werner CM, et al. Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length. Eur Heart J 2019.[63]
- Sánchez-González JL, et al. Effects of physical exercise on telomere length in healthy adults: systematic review, meta-analysis, and meta-regression. JMIR Public Health Surveill 2024.[64]
- Gutierrez-Rodrigues F, et al. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One 2014.[65]
- Martin-Ruiz CM, et al. Reproducibility of telomere length assessment: an international collaborative study. Int J Epidemiol 2015.[66]
- Salvador L, et al. A natural product telomerase activator lengthens telomeres in humans: a randomized, double blind, and placebo controlled study. Rejuvenation Res 2016.[67]
- Burke KE, et al. The safety of oral telomerase activator in UV-induced skin cancer, with a review of telomerase in aging and skin carcinogenesis. OBM Geriatrics 2021.[68]
- Whittemore K, et al. Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice. Aging (Albany NY) 2019.[69]